BOSTON, April 22, 2025 -- PhaseV, a leader in AI/ML-driven clinical development, today announced that the second episode in its webinar series will focus on improving patient-centricity and efficiency in clinical trial design.
The session Putting Patients First: Novelty, Adaptivity, and Collaboration in Clinical Development, will air on Thursday, May 1, 2025, at 1:00 PM EST. Click here to register for the webinar, which will feature industry leaders exploring how patient-centric approaches are shaping adaptive trial design and driving more efficient clinical development:
- Angela Dobes, Senior Vice President, IBD Plexus, Crohn's & Colitis Foundation
- Oren Hershkovitz, PhD, CEO, Enlivex Therapeutics
- Aaron Galluzzi, Consulting Statistician, Alimentiv
Moderated by Keren Peri-Hanania, MD, Medical Director at PhaseV, the panel will discuss:
- How patient-centricity in trial design increases efficiency in clinical development
- The integration of real-world data with causal and adaptive methods to improve patient stratification and enhance trial results
- The role of patient advocacy organizations in connecting sponsors, patients, and technology developers to increase the inclusivity and impact of new research
- The importance of collaboration, providing examples of biotech sponsors, CROs, foundations, and technology providers working together to accelerate drug development while prioritizing patient needs
"Our webinar series is more than a discussion, it's an opportunity to share the practical insights we've gained in clinical development to help drive meaningful change in the field," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "Participants will gain actionable strategies to incorporate new AI-driven approaches, real-time data and patient-centered design into their trials for more efficient and effective clinical development."
About PhaseV
PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by up to 25%, decreased enrollment size and trial duration by up to 40%, and increased the probability of trial success by over 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.
Learn more at www.PhaseVTrials.com and follow us on LinkedIn.
Infographic: https://mma.prnewswire.com/media/2669104/PhaseV_Infographic.jpg
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
